Serenex Inc has signed an agreement with GlaxoSmithKline to incorporate Serenex's novel chemoproteomics technologies into selected GSK drug discovery programs. The companies will evaluate how these technologies impact the process of identifying the best compounds to advance to drug development.

The agreement provides GSK with access to Serenex's unique Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against thousands of protein targets simultaneously. These proprietary processes help to quickly provide previously unobtainable target/compound binding information of unprecedented breadth, improving the timeliness and quality of decisions about the development of drug candidates.

Richard S. Kent, president and chief executive officer of Serenex, said, "We believe our technologies are tremendous tools to accelerate the drug discovery and development process by providing higher quality, more comprehensive data more rapidly than standard screening approaches. We are pleased to apply our technologies to the discovery programs at GlaxoSmithKline."